Subtype
Ovarian Neoplasm
CI-CAN-00001335Explore in graph →
Non-malignant746 active trials5 approved drugs94 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001335Explore in graph →
Clinical trials
3,430 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07694427 | Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03] | not yet recruiting | Phase 3 | 720 | GlaxoSmithKlineINDUSTRY | 0 | Sep 25, 2026 | clinicaltrials |
| NCT07743164 | A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) | not yet recruiting | Phase 3 | 646 | Merck Sharp & Dohme LLCINDUSTRY |
| 0 |
| Sep 11, 2026 |
| clinicaltrials |
| NCT07811271 | Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers | not yet recruiting | Phase 3 | 600 | BeOne MedicinesINDUSTRY | 0 | Sep 10, 2026 | clinicaltrials |
| NCT07797283 | Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1(MAESTRA 3) | not yet recruiting | Phase 3 | 590 | Incyte CorporationINDUSTRY | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07684612 | A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02) | not yet recruiting | Phase 3 | 690 | GlaxoSmithKlineINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07791732 | A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03) | not yet recruiting | Phase 3 | 600 | Daiichi SankyoINDUSTRY | 0 | Sep 1, 2026 | clinicaltrials |
| NCT07779538 | Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer | not yet recruiting | Phase 3 | 420 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07545460 | A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | not yet recruiting | Phase 3 | 404 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07286162 | Trauma-Focused Managing Cancer And Living Meaningfully (CALM-TF) for Newly Diagnosed and Recurrent Ovarian Cancer(CALM-TF) | not yet recruiting | Phase 3 | 300 | University Health Network, TorontoOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07068464 | ICRA Randomised Controlled Trial(ICRA) | not yet recruiting | Phase 3 | 682 | NHS GrampianOTHER_GOV | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06990503 | SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer | not yet recruiting | Phase 3 | 300 | Tongji HospitalOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT06751485 | JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer | not yet recruiting | Phase 3 | 430 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 0 | Dec 31, 2024 | clinicaltrials |
| NCT06542549 | Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer | not yet recruiting | Phase 3 | 100 | Anhui Provincial HospitalOTHER_GOV | 0 | Aug 7, 2024 | clinicaltrials |
| NCT06539091 | Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer | not yet recruiting | Phase 3 | 51 | Anhui Provincial HospitalOTHER_GOV | 0 | Aug 6, 2024 | clinicaltrials |
| NCT05924776 | Plasmodium Immunotherapy for Advanced Ovarian Cancer | not yet recruiting | Phase 2 / Phase 3 | 30 | CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.INDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06188455 | Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer | not yet recruiting | Phase 3 | 37 | The First Affiliated Hospital of Xiamen UniversityOTHER | 0 | Jan 3, 2024 | clinicaltrials |
| NCT04515602 | Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS) | not yet recruiting | Phase 3 | 410 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Aug 27, 2020 | clinicaltrials |
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials